BioSpace News Archive

The delay and guidance downgrade follow a spate of operational issues that have affected three of Catalent’s major manufacturing sites.

The pharma company will lay off 170 employees and drop all candidates but one, as it seeks to rebuild its business.

The layoffs come as the company posts nearly $300 million in net losses and just over $80 million in revenue during the first quarter of 2023.

Clinical lab techs are in high demand in healthcare, pharma and biotech. Here’s a look at what they do, career advancement opportunities within the role and the training required to become one.

Universal Diagnostics today announced the results of a large international multi-cohort case-control which demonstrate that cell-free DNA methylation and fragmentation signals combined with machine-learning can be used to detect early-stage colorectal cancer (CRC) with 91% and pre-cancerous advanced adenomas (AA) with 54% sensitivity at 92% specificity.

Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today that based on the most recent scientific and clinical evidence, the ACR Committee on Drugs and Contrast Media has classified Elucirem™ (gadopiclenol) as a Group II agent.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced new long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).

SAB Biotherapeutics today announced the U.S. Food and Drug Administration has approved five of seven sections required for the Company’s pending New Animal Drug Application (NADA) for the company’s antibody-generating platform in Transchromosomic (Tc) bovine.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego.